Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER	PATIENT:
Name:	Name:
Ward:	NHI:
Pomalidomide	
INITIATION – Relapsed/refractory plasma cell dyscrasia Re-assessment required after 6 months	
Prerequisites (tick boxes where appropriate)	
Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.	
Patient has relapsed or refractory plasma cell dyscrasia, not including Waldenström macroglobulinaemia, requiring treatment O Patient has not received prior funded pomalidomide	
CONTINUATION – Relapsed/refractory plasma cell dyscrasia Re-assessment required after 12 months Prerequisites (tick box where appropriate)	
Prescribed by, or recommended by any relevant practitioner, or in acc NZ Hospital.	cordance with a protocol or guideline that has been endorsed by the Health
Patient has no evidence of disease progression	